106590-26-5

Basic information

• Product Name: 3-[(4-nitrobenzoyl)amino]benzoic acid
• Synonyms: 3-[(4-nitrobenzoyl)amino]benzoic acid
• CAS NO: 106590-26-5
• Molecular Formula: C₁₄H₁₀N₂O₅
• Molecular Weight: 286.24
• Mol File: 106590-26-5.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-[(4-nitrobenzoyl)amino]benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(4-nitrobenzoyl)amino]benzoic acid(106590-26-5)
• EPA Substance Registry System: 3-[(4-nitrobenzoyl)amino]benzoic acid(106590-26-5)

Safety Data

• Hazardous Substances Data: 106590-26-5(Hazardous Substances Data)

Upstream product

• 39799-71-8 methyl 3-(4-nitrobenzamido)benzoate 
• 4518-10-9 Methyl 3-aminobenzoate 
• 99-05-8 meta-aminobenzoic acid 
• 122-04-3 4-nitro-benzoyl chloride 
• 62-23-7 4-nitro-benzoic acid 

Downstream Products

• 83900-78-1 3-(4-amino-benzoylamino)-benzoic acid 

Relevant articles and documents

A Practical and High-Affinity Fluorescent Probe for Butyrylcholinesterase: A Good Strategy for Binding Affinity Characterization

Butyrylcholinesterase (BChE) is regarded as a promising target for the treatment of Alzheimer's disease (AD), as its level significantly increases along with the progress of this disease. Therefore, the development of potent and high-affinity small-molecule BChE inhibitors may be a new strategy for the discovery of anti-AD drugs. However, the current Ellman's method is unable to evaluate the affinity of compounds with BChE, and has a few deficiencies in drug development. Herein, the first small-molecule fluorescence polarization (FP) probes for BChE were rationally designed based on a high affinity inhibitor. Studies indicated that probe F6 exhibited satisfactory fluorescence intensity and suitable fluorescent properties that were compatible with the filters in the FP system. Meanwhile, probe F6 exhibited potent binding affinity to BChE. It is feasible to be applied in detecting the affinity of non-fluorescent compounds to BChE, which lays a solid foundation for the development of small-molecule BChE inhibitors. At the same time, it also can be applied as a valuable chemical tool for better understanding the molecular biological mechanism of BChE.

PHARMACEUTICAL COMPOSITION FOR INHIBITING THE TRANSCRIPTION FACTOR INDUCIBLE BY HYPOXIA, MODULATORS OF PATHOLOGICAL PROCESSES OF ANGIOGENESIS, ONCOGENESIS, INFLAMMATION, APOPTOSIS, AND CELLULAR THERAPY

The present invention is included in the field of pharmacology and medical chemistry and relates to novel molecules represented by general formula (I), especially the one called FM19G11, as well as to pharmaceutical compositions containing them. Said pharmacologically optimized compositions are capable of modulating and/or inhibiting the transcription of genes modulated by the hypoxia-inducible transcription factor (HIF) and which are directly and/or indirectly involved in pathological processes related to cancer, inflammation, tissue repair, stem cell differentiation and regenerative therapy. The present invention also relates to a method for the synthesis of said molecules (I) and to the use thereof in the manufacture of a medicament for the treatment of the mentioned pathological processes.